Quince Therapeutics, Inc. financial data

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, CA
State of incorporation
CA
Fiscal year end
December 31
Former names
Cortexyme, Inc. (to 8/1/2022)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 699 % -65.7%
Debt-to-equity 173 % +562%
Return On Equity -116 % -219%
Return On Assets -42.5 % -47.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44M shares +1.82%
Common Stock, Shares, Outstanding 44M shares +2.39%
Entity Public Float 23.2M USD -53.6%
Common Stock, Value, Issued 44K USD +2.33%
Weighted Average Number of Shares Outstanding, Basic 43.3M shares +16.2%
Weighted Average Number of Shares Outstanding, Diluted 43.3M shares +16.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.6M USD +96.8%
General and Administrative Expense 17.6M USD -0.65%
Operating Income (Loss) -57.3M USD -65.5%
Income Tax Expense (Benefit) 87K USD -86.3%
Net Income (Loss) Attributable to Parent -56.8M USD -81.1%
Earnings Per Share, Basic -1.31 USD/shares -56%
Earnings Per Share, Diluted -1.31 USD/shares -56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.8M USD -3.49%
Cash, Cash Equivalents, and Short-term Investments 40.8M USD -45.7%
Other Assets, Current 84K USD +3.7%
Assets, Current 44M USD -43.1%
Property, Plant and Equipment, Net 315K USD +34.6%
Operating Lease, Right-of-Use Asset 498K USD +29.4%
Intangible Assets, Net (Excluding Goodwill) 60M USD -5.7%
Goodwill 0 USD -100%
Other Assets, Noncurrent 9.58M USD +12.2%
Assets 114M USD -31.8%
Accounts Payable, Current 2.9M USD +42.8%
Accrued Liabilities, Current 4.38M USD +27.3%
Liabilities, Current 7.28M USD -24%
Deferred Income Tax Liabilities, Net 4.96M USD -6.43%
Operating Lease, Liability, Noncurrent 394K USD +22.7%
Other Liabilities, Noncurrent 685K USD +16.7%
Liabilities 84.3M USD +1.83%
Accumulated Other Comprehensive Income (Loss), Net of Tax -35K USD -101%
Retained Earnings (Accumulated Deficit) -376M USD -17.8%
Stockholders' Equity Attributable to Parent 30.1M USD -64.6%
Liabilities and Equity 114M USD -31.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.35M USD -134%
Net Cash Provided by (Used in) Financing Activities 190K USD +280%
Net Cash Provided by (Used in) Investing Activities 8.91M USD +60.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44M shares +2.39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD -50.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.21M USD -70.1%
Deferred Tax Assets, Valuation Allowance 91.5M USD +7.49%
Deferred Tax Assets, Gross 103M USD +5.9%
Operating Lease, Liability 490K USD +27.3%
Payments to Acquire Property, Plant, and Equipment 39K USD -71.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -59.9M USD -114%
Lessee, Operating Lease, Liability, to be Paid 596K USD +27.1%
Operating Lease, Liability, Current 96K USD +50%
Lessee, Operating Lease, Liability, to be Paid, Year Two 132K USD +45.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 135K USD +48.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 106K USD +27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 126K USD +43.2%
Deferred Tax Assets, Operating Loss Carryforwards 87.2M USD +6.48%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.43M USD +2.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 214K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.7M USD -5.1%
Share-based Payment Arrangement, Expense 4.75M USD -9.08%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%